34
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Thiram inhibits angiogenesis and slows the development of experimental tumours in mice

      research-article
      1
      British Journal of Cancer
      Nature Publishing Group
      angiogenesis, SOD-1, thiram, oxidative stress, endothelial cells

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Thiram-tetramethylthiuram disulphide – a chelator of heavy metals, inhibited DNA synthesis and induced apoptosis in cultured bovine capillary endothelial cells. Bovine capillary endothelial cells were 10–60-fold more sensitive to thiram than other cell types. These effects were prevented by addition of antioxidants, indicating involvement of reactive oxygen species. Exogenously added Cu 2+ impeded specifically and almost completely the inhibitory effect of thiram for bovine capillary endothelial cells. Moreover, thiram had markedly inhibited human recombinant Cu/Zn superoxide dismutase enzymatic activity (85%) in vitro. Moreover, PC12-SOD cells with elevated Cu/Zn superoxide dismutase were less sensitive to thiram treatment than control cells. These data indicate that the effects of thiram are mediated by inhibition of Cu/Zn superoxide dismutase activity. Oral administration of thiram (13–30 μg mouse −1), inhibited angiogenesis in CD1 nude mice. Tumour development is known to largely depend on angiogenesis. We found that oral administration of thiram (30 μg) to mice caused significant inhibition of C6 glioma tumour development (60%) and marked reduction (by 3–5-fold) in metastatic growth of Lewis lung carcinoma. The data establish thiram as a potential inhibitor of angiogenesis and raise the possibility for its use as therapy in pathologies in which neovascularisation is involved, including neoplasia.

          British Journal of Cancer (2002) 86, 779–787. DOI: 10.1038/sj/bjc/6600078 www.bjcancer.com

          © 2002 Cancer Research UK

          Related collections

          Most cited references60

          • Record: found
          • Abstract: found
          • Article: not found

          Angiogenesis in cancer, vascular, rheumatoid and other disease.

          J Folkman (1995)
          Recent discoveries of endogenous negative regulators of angiogenesis, thrombospondin, angiostatin and glioma-derived angiogenesis inhibitory factor, all associated with neovascularized tumours, suggest a new paradigm of tumorigenesis. It is now helpful to think of the switch to the angiogenic phenotype as a net balance of positive and negative regulators of blood vessel growth. The extent to which the negative regulators are decreased during this switch may dictate whether a primary tumour grows rapidly or slowly and whether metastases grow at all.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Oxygen-derived free radicals in postischemic tissue injury.

            J M McCord (1985)
            It is now clear that oxygen-derived free radicals play an important part in several models of experimentally induced reperfusion injury. Although there are certainly multiple components to clinical ischemic and reperfusion injury, it appears likely that free-radical production may make a major contribution at certain stages in the progression of the injury. The primary source of superoxide in reperfused reoxygenated tissues appears to be the enzyme xanthine oxidase, released during ischemia by a calcium-triggered proteolytic attack on xanthine dehydrogenase. Reperfused tissues are protected in a variety of laboratory models by scavengers of superoxide radicals or hydroxyl radicals or by allopurinol or other inhibitors of xanthine oxidase. Dysfunction induced by free radicals may thus be a major component of ischemic diseases of the heart, bowel, liver, kidney, and brain.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

              Clinical and experimental studies suggest that angiogenesis is a prerequisite for solid tumour growth. Several growth factors with mitogenic or chemotactic activity for endothelial cells in vitro have been described, but it is not known whether these mediate tumour vascularization in vivo. Glioblastoma, the most common and most malignant brain tumour in humans, is distinguished from astrocytoma by the presence of necroses and vascular proliferations. Here we show that expression of an endothelial cell-specific mitogen, vascular endothelial growth factor (VEGF), is induced in astrocytoma cells but is dramatically upregulated in two apparently different subsets of glioblastoma cells. The high-affinity tyrosine kinase receptor for VEGF, flt, although not expressed in normal brain endothelium, is upregulated in tumour endothelial cells in vivo. These observations strongly support the concept that tumour angiogenesis is regulated by paracrine mechanisms and identify VEGF as a potential tumour angiogenesis factor in vivo.
                Bookmark

                Author and article information

                Journal
                Br J Cancer
                British Journal of Cancer
                Nature Publishing Group
                0007-0920
                1532-1827
                04 March 2002
                : 86
                : 5
                : 779-787
                Affiliations
                [1 ]Department of Animal Sciences, Faculty of Agriculture, Hebrew University of Jerusalem, Rehovot 76100, Israel
                Author notes
                [* ]Author for correspondence: marikovs@ 123456agri.huji.ac.il
                Article
                6600078
                10.1038/sj.bjc.6600078
                2375322
                11875743
                ca9337f4-74d4-4cae-a14c-7d4203a29bb0
                Copyright 2002, Cancer Research UK
                History
                : 26 July 2001
                : 12 November 2001
                : 13 November 2001
                Categories
                Experimental Therapeutics

                Oncology & Radiotherapy
                thiram,sod-1,oxidative stress,endothelial cells,angiogenesis
                Oncology & Radiotherapy
                thiram, sod-1, oxidative stress, endothelial cells, angiogenesis

                Comments

                Comment on this article